Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
Aesthetic Surgery Journal|March 4, 2025
Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II StudyMichael Gold, Joel Schlessinger, Greg J Goodman, et al.Clinical Pharmacology in Drug Development|January 8, 2024
Pharmacokinetics, Safety, and Tolerability of a Single 5-Day Treatment of Tirbanibulin Ointment 1% in 100 cm2 : A Phase 1 Maximal-Use Trial in Patients with Actinic KeratosisJanet DuBois, Terry M Jones, Mark S Lee, et al.American Journal of Clinical Dermatology|October 29, 2021
Tapinarof Cream 1% for Extensive Plaque Psoriasis: A Maximal Use Trial on Safety, Tolerability, and PharmacokineticsJohn E Jett, Michael McLaughlin, Mark S Lee, et al.Journal of Drugs in Dermatology : JDD|December 1, 2018
Topical Oxymetazoline Cream 1.0% for Persistent Facial Erythema Associated With Rosacea: Pooled Analysis of the Two Phase 3, 29-Day, Randomized, Controlled REVEAL TrialsLinda Stein-Gold, Leon Kircik, Zoe Diana Draelos, et al.Aesthetic Surgery Journal|July 14, 2026
Safety and Efficacy of TrenibotulinumtoxinE for Moderate-to-Severe Glabellar Lines: A Phase 2b, Double-Blind, Placebo-Controlled, Dose-Escalation StudyEdward Lain, Leslie Baumann, Suzanne Bruce, et al.Journal of the American Academy of Dermatology|February 8, 2018
WITHDRAWN: Efficacy and safety of topical oxymetazoline cream 1.0% for treatment of persistent facial erythema associated with rosacea: findings from the 2 phase 3, 29-day, randomized, controlled REVEAL trialsLinda Stein-Gold, Leon H Kircik, Zoe Diane Draelos, et al.Allergy|November 20, 2023
Clinical and molecular effects of oral CCR4 antagonist RPT193 in atopic dermatitis: A Phase 1 studyRobert Bissonnette, Janet DuBois, Paola Facheris, et al.Science Advances|May 1, 2024
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1Kavita Y Sarin, Mark Bradshaw, Chris O'Mara, et al.JAMA Dermatology|May 7, 2025
Roflumilast Foam, 0.3%, for Psoriasis of the Scalp and Body: The ARRECTOR Phase 3 Randomized Clinical TrialMelinda J Gooderham, Javier Alonso-Llamazares, Jerry Bagel, et al.The British Journal of Dermatology|June 6, 2023
Once-daily roflumilast foam 0.3% for scalp and body psoriasis: a randomized, double-blind, vehicle-controlled phase IIb studyLeon H Kircik, Javier Alonso-Llamazares, Neal Bhatia, et al.Pageof 3